Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

Background: Temozolomide shows activity against medulloblastoma, the most common malignant paediatric brain tumour. Poly(ADP-ribose) polymerase (PARP) inhibitors enhance temozolomide activity in extracranial adult and paediatric human malignancies. Methods: We assessed the effect of AG-014699, a cli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2010-11, Vol.103 (10), p.1588-1596
Hauptverfasser:	Daniel, R A, Rozanska, A L, Mulligan, E A, Drew, Y, Thomas, H D, Castelbuono, D J, Hostomsky, Z, Plummer, E R, Tweddle, D A, Boddy, A V, Clifford, S C, Curtin, N J
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/436/1729 631/378/1689/1690 692/308/2778 692/700/565/1436/1437 Animals Antineoplastic Agents, Alkylating - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Brain cancer Brain research Cancer Research Cancer therapies Cell Division - drug effects Cell Line, Tumor Cell Survival - drug effects Central Nervous System Neoplasms - drug therapy Central Nervous System Neoplasms - enzymology Central Nervous System Neoplasms - pathology Child Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use DNA damage DNA methylation DNA Mismatch Repair - drug effects DNA Repair - drug effects Drug Resistance Epidemiology Humans Indoles - therapeutic use Medical research Medical sciences Medulloblastoma - drug therapy Medulloblastoma - enzymology Medulloblastoma - pathology Mice Mice, Nude Molecular Medicine Nervous system Neurology Oncology Pediatrics Poly (ADP-Ribose) Polymerase-1 Poly(ADP-ribose) Polymerase Inhibitors Protein Serine-Threonine Kinases - antagonists & inhibitors Temozolomide Toxicity Translational Therapeutics Transplantation, Heterologous Tumors Tumors of the nervous system. Phacomatoses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!